Khang & Khang LLP (the “Firm”) announces that it is investigating claims against ZIOPHARM Oncology, Inc. (“ZIOPHARM” or the “Company”) (Nasdaq: ZIOP) concerning possible violations of federal securities laws.
If you purchased shares of ZIOPHARM and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s July 14, 2016 announcement that a brain cancer patient in a clinical trial for its experimental gene therapy, Ad-RTS-hIL-12, died and that there was a second patient death in a gene therapy study unrelated to the Ad-RTS-hIL-12 one. The spokesperson stated that the Company did not yet inform the U.S. Food & Drug Administration about the death. Upon release of this news, stock prices of ZIOPHARM fell. The Company was trying to raise $50 million in a stock offering that week but the deal was abandoned on the night of July 14, 2016 according to an email sent by Jefferies & Co. bankers.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160720005947/en/
Contacts:
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
